VIIBRYD KIT

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

VILAZODONE HYDROCHLORIDE; VILAZODONE HYDROCHLORIDE; VILAZODONE HYDROCHLORIDE

Dostupné s:

FOREST LABORATORIES CANADA INC

ATC kód:

N06AX24

INN (Mezinárodní Name):

VILAZODONE

Dávkování:

10MG; 20MG; 40MG

Léková forma:

KIT

Složení:

VILAZODONE HYDROCHLORIDE 10MG; VILAZODONE HYDROCHLORIDE 20MG; VILAZODONE HYDROCHLORIDE 40MG

Podání:

ORAL

Jednotky v balení:

7X10MG-7X20MG-16X40MG

Druh předpisu:

Prescription

Terapeutické oblasti:

SEROTONIN MODULATORS

Přehled produktů:

Active ingredient group (AIG) number: 0357131001; AHFS:

Stav Autorizace:

CANCELLED PRE MARKET

Datum autorizace:

2018-09-13

Charakteristika produktu

_VIIBRYD_
_TM_
_ Product Monograph _
_Page 1 of 41 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
VIIBRYD
TM
vilazodone hydrochloride
10 mg, 20 mg, 40 mg tablets
ANTIDEPRESSANT
Forest Laboratories Canada Inc.
6733 Mississauga Road, Suite 400
Mississauga, Ontario
L6N 6J5
DATE OF PREPARATION:
JULY 15, 2015
SUBMISSION CONTROL NO: 176820
VIIBRYD
TM
is a trademark of Forest Laboratories, Inc., used under licence by
Forest
Laboratories Canada Inc.
©
2014 Forest Laboratories Canada Inc. All Rights Reserved.
_VIIBRYD_
_TM_
_ Product Monograph _
_Page 2 of 41 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................16
DOSAGE AND ADMINISTRATION
..............................................................................20
OVERDOSAGE
................................................................................................................21
ACTION AND CLINICAL PHARMACOLOGY
............................................................22
STORAGE AND STABILITY
..........................................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................27
PHARMACEUTICAL INFORMATION
....